• 1
    Dahlin DC, Unni KK. Osteosarcoma. In: DahlinDC, UnniKK, eds. Bone Tumors. General Aspects and Data on 8,542 Cases. Springfield, Illinois: Charles C. Thomas, 1986; 269307.
  • 2
    Paredes J, Chawla SP, Raymond AK et al. Chemotherapy of osteosarcoma of the pelvis (Abstr). Proc Am Assoc Cancer Res 1988; 29: A885.
  • 3
    Jaffe N, Knapp J, Chuang VP et al. Osteosarcomas: Intra-arterial treatment of the primary tumor with Cis-diammine-dichloro-platinum II (CDP). Angiographic, pathologic, and pharmacologic studies. Cancer 1983; 51: 402407.
  • 4
    Stratford IJ, Williamson C, Adams GE. Combination studies with misonidazole and a cis-platinum complex: Cytotoxicity and radiosensitization in vitro. Br J Cancer 1980; 41: 517522.
  • 5
    Carde P, Laval F. Effect of cis-diamminedichloroplatinum (II) and x-rays on mammalian cell survival. Int J Radiat Oncol Biol Phys 1981; 7: 929933.
  • 6
    Arcangeli G, Mauro F, Morelli D, Nervi C. Multiple daily fractionation in radiotherapy: Biological rationale and preliminary clinical experiences. Eur J Cancer 1979; 15: 10771083.
  • 7
    Douglas BG, Worth AJ. Superfractionation in glioblastoma multiforme. Results of a phase II study. Int J Radiat Oncol Biol Phys 1982; 8: 17871794.
  • 8
    Mavligit GM, Benjamin R, Patt YZ et al. Intraarterial cis-platinum for patients with inoperable skeletal tumors. Cancer 1981; 48: 14.
  • 9
    Stephens FO, Tattersall MH, Marsden W et al. Regional chemotherapy with the use of cisplatin and doxorubicin as primary treatment for advanced sarcomas in shoulder, pelvis and thigh. Cancer 1987; 60: 724735.
  • 10
    Richmond RC. Toxic variability and radiation sensitization by dichlorodiammineplatinum (II) complexes in Salmonella typhi-murium cells. Radiat Res 1984; 99: 596608.
  • 11
    Begg AC, van der Kolk H, Dewit L et al. The interaction of cis-platin and radiation on RIF-1 tumor cells in vitro. Int J Radiat Biol 1986; 5: 871884.
  • 12
    Dewit L. Combined treatment of radiation and cis-diammine-dichloroplatinum (11): A review of experimental and clinical data. Int J Radiat Oncol Biol Phys 1987; 13: 403426.
  • 13
    Haselow RE, Adams GS, Oken MM, Goudsmit A, Lerner HJ, Marsh JC. Simultaneous cis-platinum (DdP) and radiation therapy (RT) for locally advanced unresectable head and neck cancer (Abstr). Proc Am Soc Clin Oncol 1983; 2: 160.
  • 14
    Schmitt G, Higi M, Stupp H, Scherer E. Ein neues interdisziplin-ares behandlungskonzept bei fortgeschrittenen interdisziplin-ares behandlungskinzept bei fortgeschrittenen Kopf-Hals-Tumoren. Strahlentherapie 1983; 159: 470473.
  • 15
    Shipley WU, Coombs LJ, Einstein AB Jr, Soloway MS, Wajsman Z, Prout GR. National Bladder Cancer Collaborative Group A: Cisplatin and full dose irradiation for patients with invasive bladder carcinoma: A preliminary report of tolerance and local response. J Urol 1984; 132: 899903.
  • 16
    Eapen L, Stewart D, Danjoux C et al. Intraarterial cisplatin and concurrent radiation for locally advanced bladder cancer. J Clin Oncol 1989; 7: 230235.
  • 17
    Rettenmaier MA, Moran MF, Ramsinghani NF. Treatment of advanced and recurrent squamous carcinoma of the uterine cervix with constant intraarterial infusion of cisplatin. Cancer 1988; 61: 13011303.
  • 18
    Tobias JS, Smith BJ, Blackman G, Finn G. Concurrent daily cisplatin and radiotherapy in locally advanced squamous carcinoma of the head-and-neck and bronchus. Radiother Oncol 1987; 9: 263268.
  • 19
    Raghavan D, Grundy R, Grenaway TM. Pre-emptive (neo-adjuvant) chemotherapy prior to radical radiotherapy for fit septuagenarians with bladder cancer: Age itself is not a contra-indication. Br J Urol 1988; 62: 154159.
  • 20
    Martinez A, Goffinet DR, Donaldson SS, Bagshaw MA, Kaplan HS. Intraarterial infusion of radiosensitizer (BudR) combined with hypofractionated irradiation and chemotherapy for primary treatment of osteogenic sarcoma. Int J Radiat Oncol Biol Phys 1985; 11: 123128.
  • 21
    Winkler K, Bielack S, Delling G et al. Effect of intraarterial versus intravenous cisplatin in addition to systemic doxorubicin, high-dose methotrexate, and ifosfamide on histologic tumor response in osteosarcoma (Study COSS-86). Cancer 1990; 66: 17031710.
  • 22
    Stewart DJ, Benjamin RS, Zimmerman S et al. Clinical pharmacology of intraarterial cis-diamminedichloroplatinum (II). Cancer Res 1983; 43: 917920.
  • 23
    Campbell TN, Howell SB, Pfeifle CE, Wung WE, Bookstein J. Clinical pharmacokinetics of intraarterial cisplatin in humans. J Clin Oncol 1983; 1: 755762.
  • 24
    Cox JD, Pajak TF, Marcial VA et al. Interfraction interval is major determinant of late effects, but not acute effects or tumor control, with hyperfractionated irradiation (HFX) of carcinomas of upper respiratory and digestive tracts (URDT) (Abstr). Int J Radiat Oncol Biol Phys 1990; 19: 196.
  • 25
    Jaffe N, Robertson R, Ayala A et al. Comparison of intra-arterial cis-diamminedichloroplatinum-II with high dose methotrexate and citrovorum factor rescue in the treatment of primary osteosarcoma. J Clin Oncol 1985; 3: 11011104.
  • 26
    Jaffe N, Raymond AK, Ayala A et al. Effect of cumulative courses of intraarterial ds-diamminedichloroplatinum-II on the primary tumor in osteosarcoma. Cancer 1989; 63: 6367.
  • 27
    Bielack S, Erttmann R, Purfurst C et al. Platinum (PT) levels in plasma (PL), ultrafiltrate (UF), urine, and tumor-tissue after intraarterial (IA) vs intravenous (IV) infusion of cis-diamminedichloroplatinum (CDDP) for osteosarcoma (OS) Proc ASCO 1988; 7: A211.
  • 28
    Hudson M, Jaffe MR, Jaffe N et al. Pediatric osteosarcoma: Therapeutic strategies, results, and prognostic factors derived from a 10-year experience. J Clin Oncol 1990; 8: 19881997.